In recent years, significant progress has been made in understanding the genetic factors underlying various ophthalmic diseases. The development of relevant animal models has played a crucial role in advancing preclinical research, including the study of disease mechanisms, drug target identification, and evaluation of treatment efficacy.
Cyagen has created a series of gene-edited models for ophthalmic diseases, such as Leber Congenital Amaurosis 2 (LCA2), Leber Congenital Amaurosis 10 (LCA10), retinitis pigmentosa, retinal degeneration, age-related macular degeneration, and corneal endothelial dysfunction. These models exhibit well-defined phenotypic characteristics and offer stable and heritable genetic traits, making them valuable tools for various ophthalmology-related investigations.
Additionally, Cyagen provides a specialized platform for ophthalmic pharmacology analysis. This comprehensive service covers ocular drug administration, in vivo ocular detection, ocular tissue collection, histological analysis, and gene and protein expression detection, ensuring integrate evaluation of ophthalmic drug efficacy.
Validated Ophthalmic Disease Models
| Product ID | Product Name | Related Diseases | Targeting Type |
|---|---|---|---|
| C001395 | hVEGFA-TG | Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) | Humanization(TG) |
| C001396 | B6-hRho | Retinitis Pigmentosa (RP) | Humanization(KI) |
| C001384 | Pde6b KO | Retinitis Pigmentosa (RP), Congenital Stationary Night Blindness (CSNB) | KO |
| C001385 | Prph2 KO | Retinitis Pigmentosa (RP), Age-related Macular Degeneration (AMD), Macular Dystrophy (MDs) | KO |
| C001386 | Tub-KO | Retinal Degeneration (RD) | KO |
| C001387 | Rpe65 KO | Retinal Degeneration (RD), Leber Congenital Amaurosis 2 (LCA2) | KO |
| C001360 | B6-Rpe65 R44X | Leber Congenital Amaurosis 2 (LCA2) | Mu |
| C001425 | Nr2e3 KO | Enhanced S Cone syndrome, ESCS; Retinitis pigmentosa, RP | KO |
Other Ophthalmic Disease Models
| Related Diseases | Target Gene | Targeting Type |
|---|---|---|
| Macular degeneration | Vegfa | Humanization(KI) |
| Abca4(Abcr) | KO, CKO, Humanization | |
| Retinitis pigmentosa, RP | Rho | KO, CKO, Humanization(WT, MU) |
| Mertk | KO, CKO | |
| Rpgr | KO, CKO | |
| Crb1 | KO, CKO | |
| Rd1(Pde6b) | MU | |
| Rd10(Pde6b) | MU | |
| Rp2 | KO, CKO | |
| Retinal Degeneration Slow, RDS | Prph2 | KO, CKO |
| Leber's congenital amaurosis 4, LCA4 | Aipl1 | KO, CKO |
| Leber's congenital amaurosis 10, LCA10 | Cep290 | KO, CKO, Humanization(WT, MU) |
| Leber's congenital amaurosis 13, LCA13 | Rdh12 | KO, CKO |
| Achromatopsia, ACHM | Cnga3 | KO, CKO |
| Dystrophia endothelialis corneae | Tcf4 | KO, CKO, Humanization |
| Congenital aniridia | Pax6 | KO, CKO |
| Choroideremia, CHM | Chm | KO, CKO |
| Usher syndrome, USH | Ush2A | Humanization(WT, MU) |
| Myo7A | CKO | |
| Vitelliform macular degeneration, VMD | Best1 | KO, CKO |
| X-linked retinoschisis, RS | Rs1 | KO, CKO |
| Oculocutaneous albinism type, OCA1 | Tyr | CKO |
| Oculocutaneous albinism type 3, OCA3 | Tyrp1 | KO, CKO |
| Ocular albinism, OA | Gpr143 | KO, CKO |
| Bietti crystalline comeoretinal dystrophy, BCD | Cyp4v3 | KO, CKO |
| Corneal dystrophy, CD | Tgfbi | KO, CKO, MU, Humanization |
| Wolfram syndrome | Wfs1 | KO, CKO |
| Pseudoxanthoma Elasticum, PXE | Abcc6 | KO, CKO |
| Retinitis pigmentosa, RP/Leber's congenital amaurosis, LCA | Tub | CKO |
| Enhanced S Cone syndrome, ESCS | Nr2e3 | KO, CKO |